一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
DC-T 细胞轴是治疗非小细胞肺癌的有效靶点
英文原题：The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer.
查看英文原题
The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
树突状细胞（DC）-T细胞轴是连接固有免疫和适应性免疫的桥梁。针对肿瘤的初始免疫应答主要由成熟抗原提呈DC诱导。增强DCs与T细胞之间的交互对话可能是提高非小细胞肺癌（NSCLC）免疫应答的有效途径。本文就DCs与T细胞在NSCLC治疗中的相互作用以及这种相互作用如何影响治疗结局作一综述。
展开英文摘要原文
The dendritic cell (DC)-T cell axis is a bridge that connects innate and adaptive immunities. The initial immune response against tumors is mainly induced by mature antigen-presenting DCs. Enhancing the crosstalk between DCs and T cells may be an effective approach to improve the immune response to non-small cell lung cancer (NSCLC). In this article, a review was made of the interaction between DCs and T cells in the treatment of NSCLC and how this interaction affects the treatment outcome.
论文信息
- 作者
- Wang S、Zhang G、Cui Q、Yang Y、Wang D、Liu A、Xia Y、Li W
- 单位
- Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.China
- 文献类型
- 综述
- 期刊
- Immunity, inflammation and disease2023 Nov
- 原文标识
- PubMed 38018578 · DOI 10.1002/iid3.1099
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →